Pharmacologic inhibition of DOT1L in murine and human DNMT3A-mutated AML cells resulted in reduced proliferation, colony formation, and induction of cell death, suggesting that DOT1L could be an immediately actionable therapeutic target [104]. This evidence concerns the gene DOT1L and acute myeloid leukemia.